Why adherence matters

Tackling patient drop-out

For years, the pharmaceutical industry has grappled with a critical challenge: early patient drop-out rates in clinical studies consistently hover between 25% and 30%. This isn’t just a statistic—it’s a significant obstacle that slows scientific progress, escalates development costs, and jeopardizes our ability to bring effective new treatments to patients who need them most.

Clinical trials are meticulously structured to evaluate therapies for specific conditions under tightly controlled protocols. The premature exit of a participant—a clear manifestation of non-adherence—sends shockwaves throughout the entire process. Each early drop-out can disrupt timelines, drive up expenses, and cast doubt on the real-world effectiveness of innovative medicines and medical devices.

Addressing non-adherence and reducing early drop-out rates is not merely advantageous—it is transformative. Lower rates of non-adherence pave the way for swifter, more affordable drug and device development, deliver measurable improvements in patient health outcomes, and ease the societal and economic burden of chronic illness. By prioritizing personalized patient support and proactive engagement, we have the power to reverse the trend of non-adherence and unlock a future where groundbreaking therapies reach those in need more efficiently and effectively than ever before.

The immense costs of non-adherence

The financial impact of non-adherence in clinical studies is staggering. Each patient lost can cost up to $36,000 directly, but the ripple effect is far greater—every day of trial delay can mean $1.6 million in lost revenue at the time of market authorization. Beyond studies, non-adherence drives 67% of protocol deviations, further threatening timelines and budgets.

The stakes grow even higher once therapies reach real-world care. A quarter of patients do not follow preventive or disease management recommendations, and up to 70% may be non-adherent to complex regimens. This leads not only to diminished treatment effectiveness but also to 200,000 avoidable deaths annually in the EU, with European healthcare systems shouldering $125 billion in unnecessary costs from hospitalizations and emergency care. In the U.S., the burden is even heavier—non-optimized medication therapy costs the healthcare system between $495 billion and $673 billion each year.

Non-adherence translates into higher inpatient costs, more frequent hospitalizations, and soaring indirect expenses from lost productivity and sick days. Absenteeism alone is estimated to cost 2.5% of the EU’s GDP—about $392 billion per year—while poor health in the U.S. workplace costs $575 billion annually. Improving adherence isn’t just a healthcare priority; it’s an economic imperative with the power to transform patient lives and reduce enormous societal costs.

Compelling Reasons to Prioritize Adherence

By 2030, BioPharma’s global R&D investment is expected to soar to $343 billion, with clinical studies consuming 45–75% ($154.4–$257.3 billion) of those resources. Patient recruitment alone absorbs 6–15% ($20.6–$51.5 billion) of clinical trial budgets. Despite these massive investments, the industry faces persistent challenges: in 2024, out of 22,357 active clinical studies worldwide, more than 85% struggled to retain enough participants, the average early drop-out rate remained at 25–30%, and a staggering 95% of studies failed to meet original timelines and budgets.

The financial impact is immense—losing a single patient can cost up to $36,000, and every day a trial is delayed can mean $1.6 million in lost revenue once market authorization is at stake. While improving recruitment is critical, overcoming high drop-out rates is equally essential. Misconceptions, unrealistic expectations, and excessive burdens are leading causes of early withdrawal, disrupting trial coordination and inflating costs.

Despite efforts to make studies more patient-centric and enhance support programs, steady drop-out rates and frequent protocol deviations reveal these initiatives often fall short. Many rely on generic, digital-first solutions that overlook the unique behaviors and evolving needs of individual patients.

True progress demands a shift to personalized support—adapting to each patient’s journey, the specifics of the protocol, and changing needs over time. By embracing the patient’s perspective and delivering tailored support, we can dramatically improve retention, streamline clinical studies, and accelerate the delivery of life-changing therapies to those who need them most.

Value-Based Healthcare: The New Standard in Pharma

As value-based healthcare cements its place at the forefront of the industry, adherence-enhancing solutions are no longer optional—they are mission-critical for pharmaceutical and medical device companies. Under the current US administration, regulatory reforms are fast-tracking drug and device approvals, while reimbursement is increasingly dependent on real-world patient outcomes. In this new environment, ensuring reliable, high-quality clinical trial data is paramount. Poor adherence doesn’t just threaten efficacy results; it leads to costly delays, jeopardizes approvals, and drives development expenses sky-high. Conversely, a robust adherence strategy safeguards trial integrity, curbs participant dropout, and accelerates the journey from lab bench to bedside.

In a world where performance-based reimbursement is the rule, not the exception, adherence technologies offer a distinctive competitive edge. Ensuring that clinical trial participants remain engaged and follow protocols empowers companies to prove lasting value, demonstrate significant cost savings, and achieve the improved patient outcomes required for value-based contracts and formulary access. From digital reminders and wearable devices to behavioral nudges and personalized patient support, modern adherence tools not only boost trial compliance—they seamlessly extend into post-launch, supporting patients in the real world and strengthening the product’s value proposition at every stage.

Furthermore, these adherence solutions are perfectly aligned with the US administration’s focus on preventive care and chronic disease management. Therapies and devices that can clearly demonstrate reductions in hospitalizations or improved recovery rates are uniquely positioned for priority review in FDA pathways and are better equipped to succeed in emerging reimbursement models. In this rapidly evolving landscape, investing in adherence is more than smart strategy—it’s the key to thriving and delivering on the promise of better health for all.